Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP can be broadly divided into immunomodulators and thrombopoietin receptor agonists (TPO-RAs). Systemic glucocorticoids and TPO-RAs are the cornerstones of clinical management; however, biologics such as Roche’s Rituxan (rituximab, biosimilars) provide additional options for refractory patients. In 2018, two novel therapies for chronic ITP—Rigel Pharmaceuticals’ Tavalisse, an oral Syk inhibitor, and Dova Pharmaceuticals’ Doptelet (avatrombopag), a second-generation TPO-RA—launched in the United States. With the treatment landscape continuing to evolve, this report offers insights from real-world claims data into prescribing trends in ITP to help new players better understand current treatment practices in ITP that may help define the market niche for their emerging product.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novartis, Amgen, Dova Pharmaceuticals, Rigel Pharmaceuticals
Key drugs: Promacta (eltrombopag), Nplate (romiplostim), Doptelet (avatrombopag), Tavalisse (fostamatinib)